Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sysmex Corporation

https://www.sysmex.co.jp/en/

Latest From Sysmex Corporation

Truvian CEO Confident Blood-Testing Benchtop Could Be ‘Any Place You Go’

During a tour of Truvian’s San Diego headquarters, Medtech Insight spoke with the company’s top executives about their unique three-in-one blood-testing benchtop system, plans for FDA regulatory filing, and marketing strategy.

Diagnostics Innovation

MTI 100: Global Medtech Recovers Core Growth After A Year Like No Other

With many medtechs restructuring for core growth in the post-pandemic era, Abbott relied on organic growth in 2022 to move to the top of the global medtech ranking. The strength of the US dollar was not kind to companies reporting in local currencies on converting revenues to dollars.

Medtech 100 Commercial

Japan Sets Luxturna, Other New Prices While Cutting Selected Fast Growers

Six new drugs including Luxturna will be price-listed in Japan on 30 August, with the Novartis gene therapy set to become the second-most expensive therapeutic product in the country. Behind another round of market expansion-related price cuts for selected drugs, discussions on possible changes to the repricing system are ongoing.

Japan Regenerative Medicine

MTI 100 Review: Medtechs Drive To Keep The Status Quo In A Year Like No Other

The performances of the leading medtechs in the first year of the COVID pandemic were impossible to compare and certainly unrepresentative of normal business cycles and competitive activity. Elective care was largely put on hold and emergency needs boosted exceptional demand for certain product types. More than anything else, 2020 tested management's planning skills.

Commercial Sales & Earnings
See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Research, Analytical Equipment & Supplies
  • Medical Devices
    • Diagnostic Equipment & Supplies
  • Other Names / Subsidiaries
    • D’PULA Medical Solutions Corporation
    • Oxford Gene Technology
    • RIKEN GENESIS
    • Sysmex Egypt LLC
    • Sysmex-Inostics
    • Sysmex Middle East FZ-LLC
    • TOA Medical Electronics Co., Ltd.
    • Medicaroid, Inc
    • Medicaroid Corporation
UsernamePublicRestriction

Register